Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
RCT Crossover design	57 people; 41 (72%) with episodic cluster headache, 15 (26%) with chronic cluster headache, and 1 (2%) unclassifiable	Adverse effects with octreotide 100 micrograms with placebo